Prothrombotic markers in familial combined hyperlipidemia: Evidence of endothelial cell activation and relation to metabolic syndrome

Atherosclerosis

Volumn 175, Issue 2, 2004, Pages 345-351

  Georgieva, Anna M ^a   Cate, Hugo Ten ^b   Keulen, Eric T P ^a   Van Oerle, René ^b   Govers Riemslag, José W P ^b   Hamulyák, Karly ^b   Van Der Kallen, Carla J H ^a   Van Greevenbroek, Marleen M J ^a   De Bruin, Tjerk W A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Apo B; apolipoprotein B; HDL cholesterol; high density lipoprotein cholesterol; LDL cholesterol; low density lipoprotein cholesterol; sd LDL cholesterol; small dense LDL cholesterol; TAT; TC; TG; total cholesterol; triglycerides; waist to hip ratio; WHR

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 12A; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIUM CELL; FEMALE; FIBRINOLYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THROMBOSIS;

ADULT; ANTITHROMBIN III; BLOOD COAGULATION FACTORS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LIPOPROTEINS; MALE; MIDDLE AGED; PEPTIDE HYDROLASES; THROMBOMODULIN; TRIGLYCERIDES;

EID: 3242664628     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.04.006     Document Type: Article

References (30)

1. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest. 52:1973;1544-1568
2. Voors-Pette C., de Bruin T.W. Excess coronary heart disease in Familial Combined Hyperlipidemia, in relation to genetic factors and central obesity. Atherosclerosis. 157:2001;481-489
3. Hopkins PN, Heiss G, Ellison RC, et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia. A case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 2003.
4. van der Kallen C.J., Voors-Pette C., Bouwman F.G., et al. Evidence of insulin resistant lipid metabolism in adipose tissue in familial combined hyperlipidemia, but not type 2 diabetes mellitus. Atherosclerosis. 164:2002;337-346
5. Maseri A., Fuster V. Is there a vulnerable plaque? Circulation. 107:2003;2068-2071
6. Kereiakes D.J. The Emperor's clothes: in search of the vulnerable plaque. Circulation. 107:2003;2076-2077
7. Ridker P.M. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann. Intern. Med. 130:1999;933-937
8. Zito F., Drummond F., Bujac S.R., et al. Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation. 102:2000;2058-2062
9. Meigs J.B., Mittleman M.A., Nathan D.M., et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 283:2000;221-228
10. Thogersen A.M., Jansson J.H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 98:1998;2241-2247
11. Anand S.S., Yi Q., Gerstein H., et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation. 108:2003;420-425
12. Sramek A., Kriek M., Rosendaal F.R. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet. 362:2003;351-354
13. Stroes E., de Bruin T., de Valk H., et al. NO activity in familial combined hyperlipidemia: potential role of cholesterol remnants. Cardiovasc. Res. 36:1997;445-452
14. Avellone G., Di Garbo V., Cordova R., et al. Activation of coagulation but normal fibrinolysis in patients with type IIA hyperlipoproteinemia. Thromb. Res. 81:1996;277-282
15. Hiraga T., Shimada M., Tsukada T., Murase T. Hypertriglyceridemia, but not hypercholesterolemia, is associated with the alterations of fibrinolytic system. Horm. Metab. Res. 28:1996;603-606
16. Lundman P., Eriksson M.J., Silveira A., et al. Relation of hypertriglyceridemia to plasma concentrations of biochemical markers of inflammation and endothelial activation (C-reactive protein, interleukin-6, soluble adhesion molecules, von Willebrand Factor, and endothelin-1). Am. J. Cardiol. 91:2003;1128-1131
17. Keulen E.T., Kruijshoop M., Schaper N.C., Hoeks A.P., de Bruin T.W. Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. Arterioscler. Thromb. Vasc. Biol. 22:2002;283-288
18. Allayee H., Dominguez K.M., Aouizerat B.E., et al. Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia. J. Lipid Res. 41:2000;245-252
19. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 288:2002;2709-2716
20. Georgieva AM, Van Greevenbroek MM, Krauss RM, et al. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2004.
21. Fuster V., Fayad Z.A., Badimon J.J. Acute coronary syndromes: biology. Lancet. 353(Suppl 2):1999;SII5-SII9
22. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 23:2003;168-175
23. Kohler H.P., Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 342:2000;1792-1801
24. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 106:2002;286-288
25. Koistinen H.A., Dusserre E., Ebeling P., et al. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and type 2 diabetic subjects. Diabetes Metab Res Rev. 16:2000;364-369
26. Yki-Jarvinen H., Sutinen J., Silveira A., et al. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol. 23:2003;688-694
27. Alessi M.C., Bastelica D., Mavri A., et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol. 23:2003;1262-1268
28. de Bruin T.W.A., Georgieva A.M., Brouwers M.C., Heitink M.V., van der Kallen C.J., Greevenbroek M.M. Radiological evidence of nonalcoholic fatty liver disease in familial combined hyperlipidemia. Am J Med. 116:2004;847-849
29. Pajukanta P, Lilja HE, Sinsheimer JS, et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 2004.
30. Zietz B., Drobnik W., Herfarth H., et al. Plasminogen activator inhibitor-1 promoter activity in adipocytes is not influenced by the 4 G/5 G promoter polymorphism and is regulated by a USF-1/2 binding site immediately preceding the polymorphic region. J Mol Endocrinol. 32:2004;155-163